Schizophrenia/Psychosis

Despite the growing body of evidence that supports the existence of a specific epidemiological, genetic, and neurobiological relationship between OCD and schizophrenia, the association remains poorly understood. Here, a brief overview.

Because cognitive and negative symptoms have the greatest impact on overall recovery, interdisciplinary strategies that target these symptoms are necessary. This article offers details.

Genius and madness: does one phenomenon cause the other-or do both share a common underlying factor or mechanism? How are geniuses able to accomplish “creative fits”? The author explores both questions.

A comprehensive adjustment to life after having had a psychotic episode and diagnosis of schizophrenia is a relatively new concept. An expert describes the post-psychotic adjustment process.

A video summarizing key points of a presentation titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”

Imagine an end to psychiatric episodes that threaten job and family, no more hospitalizations, and a chance for a long life not cut short by mental illness and its complications. What can we take away from the HIV/AIDS story for the treatment of mental illness?

Are patients with schizophrenia better off without antipsychotics? Here: a point/counterpoint.

Most patients with psychiatric diagnoses present with sleep disturbances that can have as great an impact on health-related quality of life as the mental illness itself. Here are tips on treatment and chronotherapeutic applications for major depression and other disorders.

A variety of commonly used psychiatric medications increase the risk of heatstroke, leaving psychiatric patients in jails and prisons at risk.

Clearly, some with schizophrenia fare better without antipsychotic drugs. But not all. Many individuals with schizophrenia are better off taking antipsychotic drugs for long-term.

Treatment approaches to counter adverse metabolic effects associated with the atypicals.

Take-home messages on the immunology of schizophrenia and NMDA receptor encephalitis from the Schizophrenia International Research Society conference here.

What's your first impression of this Rorschach-type image? Is there a place for Rorschach measures in assessing psychotic functioning?

We talk about mental disorders as brain disorders, but what does that really mean? How does it change the way we think about autism, schizophrenia, depression, bipolar, and other illnesses? The answer to these questions are still evolving. More in this video exclusive with NIMH Director Thomas Insel, MD.

Although there is limited evidence for mind-body treatments for schizophrenia, these approaches may improve overall quality of life without associated risks. More in this slideshow.

Select natural products have been evaluated as adjunctive agents that may be combined with conventional antipsychotics, with promising preliminary findings. Music therapy, meditation, and mindfulness training may improve quality of life for individuals with schizophrenia. Details here.

Many patients report that smoking helps them with their stress and psychological disturbances. However, smoking may actually worsen some of these symptoms. When is the right time for your patients to quit?

There is renewed interest and enthusiasm for the potential pathophysiological role of inflammation and immune dysfunction in patients with schizophrenia, with evidence for abnormalities in the blood, CSF, and CNS.

Catatonia-a syndrome of disturbed motor, mood, and systemic signs (eg, rigidity, immobility, mutism, staring, posturing, waxy flexibility, echopraxia, echolalia, and stereotypies)-has led to the clarification of its appropriate treatment.

In the first of a two-part Special Report, the evaluation and management of psychosis is explored across a range of disorders and clinical contexts.

The first generation of cognitive-behavioral therapy for psychosis, when added to standard care, has demonstrated efficacy in treating patients with delusions and hallucinations. Details in this article.

Information from studies on adolescents with psychosis and a review of the evidence about the risk of suicide and suicidal behavior in this patient population.

"Psychosis Risk" can now be diagnosed as “Attenuated Psychosis Syndrome” and used to bill for insurance reimbursement. Many bearing the diagnostic label are young adolescents and adults in whom schizophrenia or any other psychotic disorder will never develop.

What percentage of patients with schizophrenia have a comorbid cannabis use disorder? Take the quiz and learn more.

At a moment when mental health is so much at the forefront of the minds of Americans and our media, it seems time, again, to try to understand the damaging views so commonly held about people with mental illness.

Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by FDA and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.

The authors evaluate the effects of nicotine and cannabis on neurocognitive function in individuals with schizophrenia and review potential pharmacological treatment strategies.

This member of the DSM-5 Work Group for Psychotic Disorders describes the 8 dimensions used to define the presentation of psychosis-the biggest and most clinically important of the changes in the schizophrenia and other psychotic disorders section.

You’ve come a long way, baby. But maybe not long enough, according to Dr Rajiv Tandon, who shared the evolution of schizophrenia diagnosis and highlighted the current status for attendees at the US Psychiatric and Mental Health Congress.

An exchange that contributes in some small way to greater interaction and synergy among all of us who are trying to do our part to relieve emotional and mental suffering.